Enliven Therapeutics, Inc. (ELVN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $42.15: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum.
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing ELVN-001, a selective BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia, with a Phase 1/2 ENABLE trial ongoing and a pivotal Phase 3 trial initiation planned for 2026. Net loss was $103.7M... Read more
Sell if holding. Engine safety override at $42.15: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.6/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductELVN-00110-K Item 1A: 'We are substantially dependent on ELVN-001. If we are unable to advance ELVN-001 through clinical development, obtain regulatory approval and ultimately commercialize or license ELVN-001, or experience significant delays in doing so, our business will be materially harmed'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $42.15: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $39.13. Score 4.6/10, moderate confidence.
Take-profit target: $44.62 (+6.0% upside). Prior stop was $39.13. Stop-loss: $39.13.
Concentration risk — Product: ELVN-001; Quality below floor (1.6 < 4.0).
Enliven Therapeutics, Inc. trades at a P/E of N/A (forward -16.7). TrendMatrix value score: 6.0/10. Verdict: Sell.
16 analysts cover ELVN with a consensus score of 4.3/5. Average price target: $51.
What does Enliven Therapeutics, Inc. do?Enliven Therapeutics is a clinical-stage biopharmaceutical company developing ELVN-001, a selective BCR-ABL tyrosine...
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing ELVN-001, a selective BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia, with a Phase 1/2 ENABLE trial ongoing and a pivotal Phase 3 trial initiation planned for 2026. Net loss was $103.7M in 2025; accumulated deficit $347.2M; no product revenue generated.